AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34596770 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Scan
Number of subjects: 40
Study 34596770 — intervention group
Group type: COMPARATOR
Intervention: CEREC Omnicam
Number of subjects: 40
Study 34596770 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Scan and CEREC Omnicam
Number of subjects: 40
Study 34596937 — intervention group
Group type: EXPERIMENTAL
Intervention: MA (intensified induction chemotherapy)
Number of subjects: 0
Study 34596937 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine (1600 mg/m2) from AAML0531 trial
Number of subjects: 0
Study 34597119 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1 g daily plus prednisone 10 mg and luteinizing hormone-releasing hormone agonist until progression or unacceptable toxicities
Number of subjects: 24
Study 34597411 — intervention group
Group type: EXPERIMENTAL
Intervention: Event Notification Service (ENS) alerts
Number of subjects: 0
Study 34597411 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no ENS alerts)
Number of subjects: 0
Study 34597414 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive tests including computed tomography (CT) scanning
Number of subjects: 1644
Study 34597414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard testing plus positron emission tomography (PET)/CT scanning
Number of subjects: 1644
Study 34598099 — intervention group
Group type: EXPERIMENTAL
Intervention: NightWatch wearable seizure detection device used for two months at home.
Number of subjects: 23
Study 34598099 — intervention group
Group type: EXPERIMENTAL
Intervention: NightWatch wearable seizure detection device
Number of subjects: 23
Study 34598702 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based diabetes shared medical appointment intervention
Number of subjects: 22
Study 34598702 — intervention group
Group type: EXPERIMENTAL
Intervention: Study team members' training on PRECIS-2 scoring
Number of subjects: 22
Study 34598702 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol refinements to achieve pragmatism
Number of subjects: 22
Study 34598945 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4830 monotherapy
Number of subjects: 84
Study 34598945 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4830 in combination with pembrolizumab
Number of subjects: 84
Study 34598945 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4830 monotherapy and combination therapy
Number of subjects: 84
Study 34599020 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1-targeted CD47 bispecific antibody
Number of subjects: 0
Study 34599023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib 120 mg daily from day 1 up to 48 hours pre-surgery and nivolumab 240 mg on day 15.
Number of subjects: 10
Study 34599023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib alone (1A)
Number of subjects: 10
Study 34599023 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib-nivolumab (1B)
Number of subjects: 10
Study 34599042 — intervention group
Group type: EXPERIMENTAL
Intervention: Second wave antibodies treatment (specific details not provided)
Number of subjects: 0
Study 34599042 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 34599144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake and gut microbiota analysis
Number of subjects: 27
Study 34599144 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) treatment
Number of subjects: 27
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 (intronic) variant rs56113850 in EA females
Number of subjects: 1785
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 (intronic) variant rs56113850 in EA males
Number of subjects: 1785
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 (~ 16 kb 3') variant rs11878604 in AA females
Number of subjects: 1785
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 (~ 7 kb 3') variant rs3865454 in AA males
Number of subjects: 1785
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: TMEM132C (~ 1 Mb 5') variant rs12425845 in AA females
Number of subjects: 1785
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC17A2 (~ 8 kb 5') variant rs9379805 in AA males
Number of subjects: 1785
Study 34599228 — intervention group
Group type: EXPERIMENTAL
Intervention: ZNF469 (~ 92 kb 5') variant rs77368288 in AA males
Number of subjects: 1785
Study 34599726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib plus lenalidomide and dexamethasone
Number of subjects: 34
Study 34599726 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lenalidomide and dexamethasone
Number of subjects: 34
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of major adverse clinical events during hospitalization (including mortality, mechanical ventilation, high-flow nasal oxygen therapy, prone positioning, sepsis, systemic inflammatory response syndrome, and embolic events)
Number of subjects: 773
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 773
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory insufficiency on admission
Number of subjects: 773
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough on admission
Number of subjects: 773
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 773
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean age of patients in combined event group
Number of subjects: 773
Study 34600119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean age of patients in non-combined event group
Number of subjects: 773
Study 34600310 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychiatric conditions
Number of subjects: 230
Study 34600310 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n = 230, age = 39.4 ± 14.9 years, 80% female)
Number of subjects: 230
Study 34600468 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab every 28 days for a period of 12 months
Number of subjects: 75
Study 34600468 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 75
Study 34600524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural context factors (religiosity and social support)
Number of subjects: 0
Study 34600524 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 0
Study 34600524 — intervention group
Group type: EXPERIMENTAL
Intervention: Religiosity
Number of subjects: 0
Study 34600524 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment
Number of subjects: 0
Study 34600527 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-GLB intervention
Number of subjects: 240
Study 34600543 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese version of the Resilience Scale for Children (RS-10)
Number of subjects: 186
Study 34600582 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted perforated lacrimal punctal plugs
Number of subjects: 29
Study 34600820 — intervention group
Group type: EXPERIMENTAL
Intervention: rhHNS IT (10 mg, 45 mg, 90 mg)
Number of subjects: 12
Study 34600872 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement
Number of subjects: 0
Study 34600873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2008
Study 34601043 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous renal transluminal angioplasty (PTRA) guided by trans-stenotic pressure measurements
Number of subjects: 24
Study 34601043 — intervention group
Group type: COMPARATOR
Intervention: Visual angiographic parameters
Number of subjects: 24
Study 34601043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure measurements made by a 4F catheter
Number of subjects: 24
Study 34601043 — intervention group
Group type: EXPERIMENTAL
Intervention: PTRA
Number of subjects: 24
Study 34601071 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (tritium-labelled)
Number of subjects: 0
Study 34601202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly 800-mg/kg total loading dose (1-week)
Number of subjects: 0
Study 34601202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly 400-mg/kg total loading dose (1-week)
Number of subjects: 0
Study 34601202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly 800-mg/kg total loading dose (2-week)
Number of subjects: 0
Study 34601202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly 100-mg/kg weekly maintenance dose
Number of subjects: 0
Study 34601202 — intervention group
Group type: EXPERIMENTAL
Intervention: Ig20Gly 200-mg/kg weekly maintenance dose
Number of subjects: 0
Study 34601579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold season in South Africa
Number of subjects: 668
Study 34601579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot season in South Africa
Number of subjects: 668
Study 34601579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold season in Tanzania
Number of subjects: 668
Study 34601579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot season in Tanzania
Number of subjects: 668
Study 34601639 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HG) assessment
Number of subjects: 233
Study 34601639 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC score, MIP, PCEF assessments
Number of subjects: 233
Study 34601639 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength correlation with MRC score
Number of subjects: 233
Study 34601639 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 233
Study 34601639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital length of stay
Number of subjects: 233
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation for COVID-19
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS3 score
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils to lymphocytes ratio
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed attempt of noninvasive positive pressure ventilation prior to intubation
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination strategy during ICU stay
Number of subjects: 868
Study 34601646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage of corticosteroids (methylprednisolone 1 mg/kg)
Number of subjects: 868
Study 34601959 — intervention group
Group type: EXPERIMENTAL
Intervention: Different rest period durations prior to blood pressure measurement
Number of subjects: 0
Study 34601970 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum potassium management (specific intervention details not provided)
Number of subjects: 0
Study 34601970 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 34602290 — intervention group
Group type: EXPERIMENTAL
Intervention: Rucaparib treatment
Number of subjects: 545
Study 34602995 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (WALK)
Number of subjects: 13
Study 34602995 — intervention group
Group type: COMPARATOR
Intervention: Seated social interactions (SOCIAL)
Number of subjects: 13
Study 34602995 — intervention group
Group type: COMPARATOR
Intervention: Simple resistance activities (SRA)
Number of subjects: 13
Study 34602995 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (WALK, SOCIAL, SRA)
Number of subjects: 13
Study 34603507 — intervention group
Group type: EXPERIMENTAL
Intervention: Q6W dosing of natalizumab
Number of subjects: 438
Study 34603507 — intervention group
Group type: COMPARATOR
Intervention: Q4W dosing of natalizumab
Number of subjects: 438
Study 34603539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 0
Study 34603539 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion dysregulation (ED)
Number of subjects: 0
Study 34604072 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg IV every 4 weeks for up to 1 year
Number of subjects: 37
Study 34604072 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 37
Study 34604082 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI) - 40 Gy in 10 fractions over 2 weeks
Number of subjects: 140
Study 34604082 — intervention group
Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 43.5 Gy in 15 fractions over 3 weeks
Number of subjects: 140
Study 34604088 — intervention group
Group type: EXPERIMENTAL
Intervention: focal prostate SBRT (f-SBRT)
Number of subjects: 18
Study 34604282 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry supplementation (concentrate or freeze-dried) for 30 days
Number of subjects: 0
Study 34604282 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34604285 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition assessment
Number of subjects: 45826
Study 34604285 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction category
Number of subjects: 45826
Study 34604341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 34604546 — intervention group
Group type: EXPERIMENTAL
Intervention: GMCD intervention plus usual care delivered by frontline workers for 12 months, using a digital mobile device interface.
Number of subjects: 624
Study 34604546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 624
Study 34604752 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg IV Q2W added to first monthly temozolomide cycle
Number of subjects: 30
Study 34604901 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg daily
Number of subjects: 109
Study 34604901 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg daily
Number of subjects: 109
Study 34604901 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid dose reduction from 1200 mg to 600 mg based on hemoglobin monitoring
Number of subjects: 109
Study 34604940 — intervention group
Group type: EXPERIMENTAL
Intervention: aSAH
Number of subjects: 150
Study 34604940 — intervention group
Group type: EXPERIMENTAL
Intervention: npmSAH
Number of subjects: 150
Study 34604940 — intervention group
Group type: EXPERIMENTAL
Intervention: pmSAH
Number of subjects: 150
Study 34605153 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP programme using smartphone-compatible data collection
Number of subjects: 969
Study 34605220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial respiratory rates
Number of subjects: 0
Study 34605220 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupling efficiency
Number of subjects: 0
Study 34605220 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofiber composition
Number of subjects: 0
Study 34605220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial reactive oxygen species production
Number of subjects: 0
Study 34605392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping in a comfortable environment
Number of subjects: 56
Study 34605392 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting naps to 30 minutes
Number of subjects: 56
Study 34605392 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining a consistent wake time
Number of subjects: 56
Study 34605392 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding alcohol use before bedtime
Number of subjects: 56
Study 34605392 — intervention group
Group type: COMPARATOR
Intervention: Actigraphy-measured sleep efficiency
Number of subjects: 56
Study 34605552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim 60 μg/kg
Number of subjects: 27
Study 34605552 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim 100 μg/kg
Number of subjects: 27
Study 34605711 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 28
Study 34605711 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 34606048 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 929
Study 34606062 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of simvastatin without switching to another statin or switching to a hydrophilic statin
Number of subjects: 34
Study 34606062 — intervention group
Group type: COMPARATOR
Intervention: Switching to lipophilic atorvastatin
Number of subjects: 34
Study 34606077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 1545
Study 34606077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 1545
Study 34606077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study 34606104 — intervention group
Group type: EXPERIMENTAL
Intervention: Skip44
Number of subjects: 142
Study 34606104 — intervention group
Group type: EXPERIMENTAL
Intervention: Skip45
Number of subjects: 142
Study 34606104 — intervention group
Group type: EXPERIMENTAL
Intervention: Skip51
Number of subjects: 142
Study 34606104 — intervention group
Group type: EXPERIMENTAL
Intervention: Skip53
Number of subjects: 142
Study 34606437 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol (75-150 mg/day for narcolepsy; 37.5-150 mg/day for OSA)
Number of subjects: 643
Study 34606501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox
Number of subjects: 1497
Study 34606501 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 1497
Study 34606665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt-abnormal children (n=10)
Number of subjects: 10
Study 34606665 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=8)
Number of subjects: 10
Study 34606692 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 168
Study 34606692 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 168
Study 34606846 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 34606846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2
Number of subjects: 0
Study 34606847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 60
Study 34606847 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization of mice with Odoribacter splanchnicus
Number of subjects: 60
Study 34606881 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) used for lymph node identification and retrieval.
Number of subjects: 0
Study 34606881 — intervention group
Group type: COMPARATOR
Intervention: Standard lymph node harvest techniques (not specified).
Number of subjects: 0
Study 34607037 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT followed by pembrolizumab
Number of subjects: 73
Study 34607210 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg BID + nivolumab + carboplatin + paclitaxel (C/PAC)
Number of subjects: 25
Study 34607210 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 240 mg BID + nivolumab + carboplatin + pemetrexed (C/PEM)
Number of subjects: 25
Study 34607210 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (80-240 mg BID) + nivolumab + C/PEM
Number of subjects: 25
Study 34607210 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 34607222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg pembrolizumab + 75 mg cisplatin, 4 cycles every 3 weeks)
Number of subjects: 26
Study 34607341 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN-α (pegIFNα) administered at 180 μg every 14 days for 4 doses starting at day -1 before HCT
Number of subjects: 36
Study 34607341 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN-α (pegIFNα)
Number of subjects: 36
Study 34607348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 0.15 mg/kg on days 1 to 5 with 8 weekly rituximab doses of 375 mg/m2 beginning day 1
Number of subjects: 20
Study 34607348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 0.15 mg/kg with rituximab
Number of subjects: 20
Study 34607348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine with rituximab
Number of subjects: 20
Study 34607348 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-negative CR at 6 months
Number of subjects: 20
Study 34607348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of MRD in blood at 6 months
Number of subjects: 20
Study 34607348 — intervention group
Group type: EXPERIMENTAL
Intervention: After progression following CDAR
Number of subjects: 20
Study 34607377 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI)
Number of subjects: 500
Study 34607377 — intervention group
Group type: COMPARATOR
Intervention: Expert Endoscopists
Number of subjects: 500
Study 34607575 — intervention group
Group type: EXPERIMENTAL
Intervention: SPCQ (single treatment with SP plus chloroquine)
Number of subjects: 1892
Study 34607575 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAZ (monthly treatment with sulphadoxine-pyrimethamine plus azithromycin)
Number of subjects: 1892
Study 34607608 — intervention group
Group type: COMPARATOR
Intervention: Health/Control
Number of subjects: 57
Study 34607608 — intervention group
Group type: EXPERIMENTAL
Intervention: Beekeeping + Health
Number of subjects: 57
Study 34607608 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrepreneurship + Health
Number of subjects: 57
Study 34607608 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrepreneurship + Beekeeping + Health
Number of subjects: 57
Study 34607609 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly matched therapy (≥ 1 therapy)
Number of subjects: 145
Study 34607609 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized combination therapies targeting molecular alterations
Number of subjects: 145
Study 34607609 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching Score (percentage of targeted alterations)
Number of subjects: 145